NSE: EMAMILTD | BSE: 531162

Mid-range Performer

Download real time

523.75 0.05 (0.01%)

92,516 NSE+BSE Volume

NSE 23 Dec, 2025 10:50 AM (IST)

22,861.7

Market Cap

Below industry Median

Beta 1Year

Very Low volatility

Emami Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for EMAMILTD, BSE:531162 Emami Ltd.

Emami Ltd.

30 Jan 2018

523.75

0.01%

Emami (3QFY18): Pain relief specialist? Yes. Maintain BUY

Buy: Emami Ltd.

HDFC Securities

We maintain BUY. Emami disappointed us on revenue growth and EBITDA margins. Net revenue was up 6% at Rs 7.6bn. Like-to-like revenue growth was slow at 10% (6% volume growth) vs. expectation of 17%. Kesh King and Health Supplements revenue contracted by 19% and 2%, impacting domestic performance. International posted healthy 16% growth, led by favorable base. EBITDA and APAT were up 2% and 4% respectively.

Number of FII/FPI investors decreased from 349 to 304 in Sep 2025 qtr

Emami Ltd.

30 Jan 2018

523.75

0.01%

Emami - 3QFY18 Result Update

Buy: Emami Ltd.

Reliance Securities

Despite lower base in 3QFY17 owing to demonetisation, Emami has reported a disappointed set of numbers for 3QFY18. While its consolidated net sales grew by 6% YoY to Rs7.6bn (vs. our estimate of Rs8.1bn), net profit came in at Rs1.5bn, lower than our estimate of Rs1.6bn....

Number of FII/FPI investors decreased from 349 to 304 in Sep 2025 qtr

Emami Ltd.

09 Jan 2018

523.75

0.01%

Emami: Rural recovery just the beginning of growth revival

Buy: Emami Ltd.

Motilal Oswal

It is a great play on rural demand growth and wholesale recovery. Before the slowdown caused by extraordinary factors like demonetization, Emami had the best track record among peers on consistency of earnings growth, which we expect will make a comeback. Emami has a formidable portfolio of dominant brands, with best-in-class R&D and advertisement to support existing brands and new launches. Despite likely resumption of better-than-peers' earnings growth of 20% CAGR over FY18-21, the stock trades in line with peer multiples. Our target price of INR1655 implies a one-year upside of 23% and a two-year upside of 39%. Our bull case upside is 33% for one year and 53% for two years.

Emami Ltd. has an average target of 656.50 from 6 brokers.

Emami Ltd.

27 Oct 2017

523.75

0.01%

Master Pick- Emami Limited

Buy: Emami Ltd.

Recommendation Target

Religare

Emami Ltd is one of the leading and fastest growing personal and healthcare businesses in India, with an enviable portfolio of household brand names such as Boroplus, Navratna, Fair and Handsome, Zandu balm, Mentho Plus balm and Fast Relief. Emami has received countless accolades for its innovative and clutter-breaking products, which have carved out whole new segments from scratch in the Indian FMCG space .

Emami Ltd. has an average target of 656.50 from 6 brokers.

Emami Ltd.

26 Oct 2017

523.75

0.01%

Emami (2QFY18): Recovery on track. Maintain BUY

Buy: Emami Ltd.

HDFC Securities

We expect EPS CAGR of 18% over FY17-20E. We value Emami based on P/E of 35x on Sep-19 EPS. Our TP is Rs 1,327. We maintain our BUY rating. Emamis net revenues were up 10% at Rs 6.3bn. Like-to-like revenues were up 14% vs. expectation of 13%. Domestic volume growth was healthy at 10% (in-line). International business registered strong 22% growth. EBITDA and APAT were up 15% and 27% respectively. Channel restocking and improving consumer sentiments have helped growth recover (1QFY18 revenue declined 16%). Management is confident of achieving ~17% domestic growth in 2HFY18. We remain optimistic about Emamis domestic business, and expect 13% revenue CAGR over FY17-20E.

Emami Ltd.'s price crossed above 30Day SMA today

Emami Ltd.

26 Oct 2017

523.75

0.01%

Emami - 2QFY18 Result Update

Buy: Emami Ltd.

Reliance Securities

Following a disappointing performance in 1QFY18 due to GST overhang, Emami has posted an encouraging set of numbers in 2QFY18. While its consolidated reported sales grew by 9.7% YoY to Rs6.3bn, the underlying revenue grew by 14% YoY excluding the accounting changes post GST. While EBITDA increased by 15% YoY to Rs2bn, net profit surged by 49.7% YoY to Rs986mn. We estimate Emami to post 12.3% revenue and 17.2% earnings CAGR through FY17-19E. We believe that Emami would sustain the growth momentum in coming quarters on the back of good monsoons, increased focus on direct distribution, strong new product pipeline and lower base effect. We maintain our BUY recommendation on the stock with a revised Target Price...

Emami Ltd. has an average target of 656.50 from 6 brokers.

Emami Ltd.

26 Oct 2017

523.75

0.01%

Emami: EBITDA above estimate; recovery seen in wholesale channel

Buy: Emami Ltd.

Motilal Oswal

2QFY18 sales grew 9.7% YoY to INR6.3b. Domestic revenue rose 14% YoY, with 10% volume growth. The quarter continued to see CSD and wholesale channel destocking, but there has been significant recovery compared to 1QFY18. HMN...

Number of FII/FPI investors decreased from 349 to 304 in Sep 2025 qtr

Emami Ltd.

26 Oct 2017

523.75

0.01%

Emami

Buy: Emami Ltd.

Sharekhan

Boroplus Cream and 7-in-one oils continue to perform well; Navratna saw recovery in sales: Boroplus range grew by 38%, driven by strong double-digit growth in Boroplus antiseptic cream. Navratna range grew by 16%, led by double-digit volume growth in cooling oil and cool talc. 7-in-one oil continued to gain good traction and registered double-digit volume...

Emami Ltd. is trading below all available SMAs

Emami Ltd.

08 Aug 2017

523.75

0.01%

Result Update - Emami

Sell: Emami Ltd.

Axis Direct

Q1FY18 below expectations: Consolidated net sales declined 16%, while EBITDA and adj PAT plummeted 46% and 56% YoY. India sales declined 16% with volume decline at ~20% YoY. International sales fell 19% due to sustained pressure in MENAP business (-42% YoY).

Emami Ltd.'s price crossed above 30Day SMA today

Is Emami Ltd. worth buying?

233 Votes:

Buy 74.25%

Sell 17.6%

Hold 8.15%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf